<DOC>
	<DOC>NCT00005921</DOC>
	<brief_summary>The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.</brief_summary>
	<brief_title>A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis</brief_title>
	<detailed_description>In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Inclusion Criteria You may be eligible for this study if you: Are an 18 to 65yearold man with candidal esophagitis.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Dose-Response Relationship, Drug</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Esophageal Diseases</keyword>
	<keyword>MK 0991</keyword>
</DOC>